Analysis of the clinical relevance of the type of chimeric mRNA in chronic myeloid leukemia in one mexican population

Cancer Research, Therapy and Control

Volumn 10, Issue 1-2, 1999, Pages 73-80

  Rosas Cabral, A ^a  

^a HOSPITAL DE ESPECIALIDADES   (Mexico)

Author keywords

Chimeric mrna; CML; Mexican population

Indexed keywords

BCR ABL PROTEIN; HEMOGLOBIN; MESSENGER RNA;

AGE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; FEMALE; FUSION GENE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEXICO; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEX DIFFERENCE; THROMBOCYTE COUNT;

EID: 0034017331     PISSN: 10640525     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Arden J.C., et al. (1993) Molecular analysis in chronic granulocytic leukemia: location of breakpoints within M-BCR and relationship with presentation platelet counts. Clin Lab Haematol. 15:253-258.
2. Aurer I., Butturini A. and Gale R.P. (1991) BCR-ABL rearrangements in children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia. Blood 78:2407-2410.
3. Bernards A., Rubin Ch.M., Westbrook C.A., Paskind M., Baltimore D. (1987) The first intron in the human c-abl gene is at least 200 kilobases long and is a target for translocation in chronic myelogenous leukemia. Moll. Cell Biol. 7:3231-3236.
4. Chomczynski P. (1993) A reagent for the single-step simultanous isolation of RNA, DNA, and proteins from cell and tissue samples. Biothecniques 15:532-537.
5. Daley G.Q., Van Etten R.A., and Baltimore D. (1990) Induction of chronic myelogenous leukemia in mice by the p210 bcr/abl gene of the Philadelphia chromosome. Science. 247, 824-830.
6. Delfau. M.H., Kerckaert J.P., D1 Hooghe M.C., Pénaux P., Lai J.L., Jouet J.P., Grandchamp B.(1991) detection of minimal residual disease in chronic myeloid leukemia patients after bone marrow transplantation by polymerase chain reaction. Leukemia 4; 1-5.
7. De Klein A, Geurts Van Kessel A, Grosveld G, Bartram C.R., Hagemeier A., Bootsma D., Spurr N.K., Heisterkamp N., Groffen J., and Sthephenson J.R (1982) A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 300:765-767.
8. Dobrovic A., Trainor K.J., Morley A.A. (1988) Detection of the molecular abnormality in chronic myeloid leukemia by use of the polymerase chain reaction. Blood. 72; 2063-2065.
9. Dreazen O., Berman m., and Gale R.P. (1988) Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. Blood. 71; 797-799.
10. Eisenberg A., Silver R., Soper L., Arlin Z., Coleman M., Bernhardt B., and Benn P. (1988) The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukermia. Leukemia 2; 642-647.
11. Fioretos et al (l 993 (clinical impact of breakpoint position within M-bcr in chronic myeloid leukemia. Leukemia 7; 1225-1231.
12. Groffen J., Stephenson J.R., Heisterkamp N., De Klein A., Bartram C.R., and Grosveld G., (1984) Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 36: 93-99.
13. Grossman et al. (1989) Fine mapping of chromosome 22 breakpoints within the breakpoint cluster region (bcr) implies a role for bcr exon 3 in determining disease duration in chronic myeloid leukemia. Am J Hum Genet. 45; 729-738.
14. Heisterkamp N., Stam K., Groffen J., De klein A., and Grosvel G. (1985) Structural organization of the BCR gene and it's role in the Ph+ translocation. Nature 315:758-761.
15. Hermans A., Heisterkamp N., Von Liddern M., Van Baal S., Meijer D., Van der Plas D., Weidemann L.M., Groffen J., Bootsma A, and Grosveld G. (1987) Unique fusion of BCR and c-ABL genes in Philadelphia chromosome positive acute lymphoblastic leukemia. Cell 51:3314.
16. Hochhaus A., Lin F., Rieter A., Skladny H., Masson P.J., Van Rhee F., Shepherd P.C., Allan N., Hehlmann R., Goldman J.M., and Cross N.C.P. (1996) Quantification of Residual Disease in Chronic Myelogenous Leukemia Patients on Interferon-a Therapy by Competitive Polymerase Chain Reaction. Blood 87: 1549-1555.
17. Inokuchi K., Inoue T, Tojo A., Futaki M., Miyake K., Yamada T., Tanabe Y., Ohki I., Dan K., Ozawa K., Asano Sh and Nomura T. (199la) A possible correlation between the type of bcr-abl hybrid messanger RNA and platelet count in Philadelphia-positive chronic myelogenous leukemia. Blood. 78; 3125-3127.
18. Inokuchi K., Futaki M., Yamada T., Tanabe Y, Dan K., Shinohara T., Kuriya Sh. and Nomura T. (1991b). The relationship between the site of breakpoints within the bcr gene and thrombopoiesis of philadelphia-positive chronic myelocitic leukemia. Leukemia res 15; 1067-1073.
19. Jaubert J., Martial P., Dowding C., Ifrah N. and Goldman J.M. (1990) The position of the M-BCR breakpoint does not predict the duration of the chronic phase or survival in chronic myeloid leukemia. Br J Haematol. 74; 30-35.
20. Jandl J.H.(1987) Chronic Myelogenous Lekemia .Blood. Textbook of Hematology. Fist Ed. 671-713. little Brown Co.
21. Lee M., Kantarjian H., Talpaz M, Deisseroth A., Freireich E., Trujillo J.M. and Stass S.A.(1989) Detection of two alternative BCR/ABL nvRNA junctions and minimal residual disease in Philadelphia chromosome positive chronic myelogenous leukemia by polimerase chain reaction. Blood. 73; 21652170.
22. Lee et al. (1990) Clinical investigation of bcr/abl splicing patterns by polimerase chain reaction in Philadelphia chromosome (Ph') positive chronic myelogenous leukemia (CML). Blood. 75(suppl l):294a
23. Mackenzie E., Stewart E. and Birnie G.D. (1993) ABL-BCR mRNAs transcribed from chromosome 9q+ in Philadelphia-chromosome-positive chronic myeloid leukemia. Leukemia. 7; 702-706.
24. Mélo J.V. (1996) The diversity of BCR-ÄBL fusion proteins and their relationship to leukemia .phenotype. Blood. 88; 23752384.
25. Melo R.A.M., Melo F.C.B.C., Lima D.F., Scaffo M.H.S., Fernades R.C., Ismael G.F.V., Bighetti J.P.M., Zago M.A., Simoes B.P. (1997). Lack of clinical relevance of the type of chimeric mRNA in chronic myelogenous leukemia:a study of 90 patients.Blood. 90; 4018a (abstr.).
26. Mills K.I., MacKenzie E.D. and Birnie G.D. (1988) The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood. 72; 1237-1241.
27. Mills K.I., Hynds S.A., Burnett A.K., MacKenzie E.D., Birnie G.D. (1989) Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) maybe a prognostic indicator. Leukemia 3: 837-839.
28. Mills K.I., Benn P. and Birnie G.D. (1991) Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood. 78; 1155-1161.
29. Morris S.W., Daniel L., Ahmed C.M.I., Elias A. and Leibowitz P. (1990) Relationship of bcr breakpoint to chronic phase duration, survival and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood. 75:2035-2041.
30. Nakamura et al.(1991) Molecular studies of chronic myelogenous leukemia using the polimerase chain reaction. Cancer. 68; 2426-2430.
31. Nowell P.C., Hungerford D.A. (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1197-1200.
32. Opalka B., Wandl U.B., Kloke O., Beer U., Seeber S. and Niederle N. (1992a). No correlation between site of breakpoinl in the bcr gene and the platelet counts in Philadelphia chromosome-positive CML.Leukemia Res. 16; 937-939.
33. Opalka B et al. ( 1992b). No correlation between the type of bcr-abl hybrid messenger RNA and platelet counts in chronic myelogenous leukemia. Blood. 80; 1854-1858.
34. Przepiorka D. (1988) Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genetics and Cytogenetics. 36; 117-122.
35. Pignon J.M., Henni T., Amselem S. (1990) Frequent detection of residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia Leukemia 4; 83-86.
36. Rozman C., Urbano-Ispizua A., Cervantes F., Rozman M., Colomer D., Féliz P. and Vives-corrons J.L.(1995). Analysis of the clinical relevance of the breakpoint location within M-BCR and the type of chimeric mRNA in chronic myelogenous leukemia. Leukemia 9; 1104-1107.
37. Shaefer-Rego. K, Dudek. M, Popenoe. D, Arlin. Z, Mears. J.G, Bank. A, and Leibowitz. D. (1987) CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood 70: 448-455.
38. Shepherd P., Bond Ch., Allan N.C. (1992) Molecular breakpoints and platelet counts in chronic myeloid leukemia. Blood. 80; 556-557.
39. Shepherd P., Sufflolk R., Halsey J. and Allan N.C. (1995) Analysis of molecular breakpoint and m-RNA transcripts in a prospective randomized trial of interferon in chronic myeloid leukaemia: no correlation with clinical features, cytogenetic response, duration of chronic phase, or survival. Br J Haematol. 89; 546-554.
40. Shtalrid M., Talpaz M., Kurzrock R., Kantarjian H., Trujillo J., Gutterman J., Yoffe G. and Blick M. (1988) Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood. 72; 485190.
41. Shitvelman E.B, Lifshitz B., Gale R.P., and Canani E.(1985) Fused transcript of abl and bcr genes in chronic myelogenous leukemia. Nature 315: 550-554.
42. Shitvelman E.B., Gale R.P., Dreazen O., Berrebi A., Zaizov R., Kubonishi ]., Miyoshi 1. and Canaani E. (1987) bcr-abl RNA in patients with chronic myelogenous leukemia. Blood. 69; 971-973.
43. Tien H.F., Wang C.H., Chen Y.C., Shen M.C., Wu H.S., Lee F.Y., Chuang S.M. and Liu C.H. (1990) Chromosome and bcr rearrangement in chronic myelogenous leukemia and their correlation with clinical states and prognosis of the disease. Br. J. Haematol. 75;469-475.
44. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Chronic myeloid leukemia, bcr/abl transcript, response to alfa-interferon and survival. Leukemia. 9; 1648-1652.
45. Wetzler M., Talpaz M, Eslrov Z., and Kurzrock R. (1993) CML: Mechanisms of disease initiation and progression. Leukemia and Lymphoma 11: 47-50.
46. Workshop (Fourth International Workshop on Chromosomes in Leukemia): Abnormalities of chromosoma 22. (1984) Cancer Genet, and Cytogenetics 11 ; 316.
47. Williams D.I., Harber J., Murphy S.B., Look A.T., Kalwinsky O.K., Rivera G., Melvin S.I., Stass S. and Dahl G.V. (1986) Chromosomal translocations play a unique role in influencing prognosis in childhood acute lymphoblastic leukemia. Blood. 68:205-212.
48. Yin J., Williams E.G., Arthur C.K. and Ma D.D.F. (1995) Interferon response in chronic myeloid leukaemia correlates with ABL/BCR expresision: a preliminary study. Br J Haematol. 89; 539-545.
49. Zaccaria A.. Martinelli G., Buzzi M., Zuffa E., Zamagni D., Testoni N., Guerrasio A., Saglio G. and Tura S. (1992) M-BCR breakpoint location does not predict survival in Philadelphia chromosome positive chronic myeloid leukemia. Haematologica. 77; 16-20.
50. Zaccaria A., Martinelli G., Buzzi M., Testoni N., Farabegoli P., Zuffa E., Zamagni M.D., Russo D., Baccarani M., Ambrosetti A., Guerrasio A., Saglio. Tura S. (1993) The type of BCR/ABL junction does not predict the survival of patients with Phi-positive chronic myeloid leukemia. Br J Haematol. 84; 265-268.